Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price target of $28.79, which represents implied upside of almost 19%. Gilead Sciences (NASDAQ:GILD) trades at $130.04 and has a $158.30 consensus target. Both stocks sit below sell-side fair value while flashing the same bearish technical warning.
Pfizer and Gilead Sciences are widely held large-cap pharma names, popular for yield, defensive characteristics, and late-stage pipelines. Investors are paying attention because both have seen a so-called death cross, the pattern where a stock’s 50-day moving average slips beneath the 200-day average. Pfizer’s 50-day is at 25.35, versus a 200-day of 25.87. Gilead’s 50-day is 129.85 against a 200-day of 130.44.
A death cross is a lagging indicator that says nothing on its own about valuation. Still, both names trade below analyst fair value with momentum rolling over. That puts the contrarian question squarely on the table.
What Broke the Bid Under Each Stock
Pfizer’s weakness is the COVID hangover colliding with a policy overhang. Recent results still show growth, with quarterly revenue up 5.4% year over year. Yet the market is fixated on Most-Favored-Nation drug pricing, potential Section 232 pharma tariffs, the IRA Medicare Part D redesign, and international Eliquis generic entry. Management has also signaled no share buybacks in 2026, removing a support pillar.
Gilead’s story is more complex. First-quarter revenue topped expectations, but the company slashed non-GAAP EPS guidance from a profit of $8.45 to $8.85 down to a loss of $0.65 to $1.05, driven by roughly $11.5 billion in IPR&D charges tied to the Arcellx, Ouro Medicines, and Tubulis acquisitions. Those are non-cash accounting items, but Wall Street hated the optics. Add in Trodelvy’s ASCENT-07 primary endpoint miss and Veklury revenue dropping 52% year over year, and momentum turned quickly.
Both selloffs have been measured. Pfizer is down 7.5% over the past month, and Gilead is off 4.6% over the past week. The bearish signal reflects drift rather than capitulation.
Why Analysts Remain Constructive on Pfizer
Wall Street analysts have mixed but generally positive views on Pfizer. The consensus target of $28.79 sits just above the 52-week high of $28.75. Ratings skew cautiously bullish.
The bull case rests on oncology (Padcev, Nurtec), the Metsera obesity acquisition, and the Vyndamax patent settlement extending U.S. exclusivity to 2031. At a forward P/E of just 8x and a 7.1% dividend yield, investors are effectively being paid to wait.
Gilead’s bull case leans on the Yeztugo launch as the first twice-yearly HIV PrEP, Biktarvy patents extended to 2036, and two major PDUFA decisions before year-end. Analysts largely framed the guidance cut as accounting noise rather than a change in underlying earnings power. HIV franchise sales grew 10% in Q1 and product gross margin expanded 200 basis points.
Readers who want the broader framework on yield-plus-growth pharma names should check out our research team’s 10 Dividend Kings to Buy Now and Hold Forever report.
How the Numbers Actually Stack Up
Pfizer is down 2.6% year to date, and Gilead is 6.0% higher, while the S&P 500 has returned 10.3% over the same stretch. Both are lagging the broader market, though Gilead’s gap is modest. On a one-year basis, Gilead is up 16.0% while Pfizer is 4.3% lower.
Pfizer’s nearly 19% implied upside is backed by a beta of 0.31 and a trailing P/E of 18x. Analyst targets are one data point, and the Hold-heavy skew makes clear that conviction is thin.
One Contrarian Buy, One Show-Me Story
The contrarian case for Pfizer rests on the COVID revenue base being fully washed through and the oncology and obesity pipeline offsetting biosimilar losses in 2027 and beyond. The forward P/E of 8x and 7% yield offer defensive cover while the pipeline matures. The bear case is that Most-Favored-Nation pricing and tariff risk structurally compress margins, in which case the dividend gets scrutinized fast if free cash flow softens.
The bull case for Gilead requires looking through the IPR&D charges and trusting that Yeztugo, Biktarvy’s 2036 patent runway, and the anito-cel and BIC/LEN PDUFAs land on schedule. The bear case is that the ASCENT-07 miss signals broader oncology execution risk, given that Gilead paid a premium for those assets.
So, Pfizer is the more compelling contrarian setup given valuation and yield support. Gilead has already recovered materially off its lows, so the easy money may already be behind it.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks